S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)

Eli Lilly and - LLY Stock Forecast, Price & News

$310.31
-3.63 (-1.16%)
(As of 08/16/2022 05:16 PM ET)
Add
Compare
Today's Range
$309.63
$314.36
50-Day Range
$288.07
$331.60
52-Week Range
$220.20
$335.33
Volume
2.25 million shs
Average Volume
2.90 million shs
Market Capitalization
$294.85 billion
P/E Ratio
49.49
Dividend Yield
1.25%
Price Target
$317.00

Eli Lilly and MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
2.2% Upside
$317.00 Price Target
Short Interest
Healthy
0.63% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.12mentions of Eli Lilly and in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$380.33 M Sold Last Quarter
Proj. Earnings Growth
17.21%
From $7.96 to $9.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

61st out of 1,124 stocks

Pharmaceutical Preparations Industry

19th out of 555 stocks

LLY stock logo

About Eli Lilly and (NYSE:LLY) Stock

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Price Performance

NYSE:LLY opened at $313.94 on Tuesday. The stock has a market capitalization of $298.30 billion, a P/E ratio of 50.07, a P/E/G ratio of 2.10 and a beta of 0.35. Eli Lilly and has a 1 year low of $220.20 and a 1 year high of $335.33. The business's fifty day moving average is $315.66 and its two-hundred day moving average is $292.40. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10.

Eli Lilly and (NYSE:LLY - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The firm had revenue of $6.49 billion for the quarter, compared to analysts' expectations of $6.85 billion. During the same quarter in the previous year, the firm posted $1.87 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and's dividend payout ratio is currently 62.52%.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. Mizuho lifted their target price on Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. StockNews.com cut Eli Lilly and from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 5th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley boosted their price target on Eli Lilly and from $369.00 to $395.00 and gave the company an "overweight" rating in a report on Friday, July 8th. Finally, Wells Fargo & Company upped their target price on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $317.00.

Insider Activity

In other news, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now directly owns 8,136 shares in the company, valued at approximately $2,477,412. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares of the company's stock, valued at approximately $2,477,412. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 700 shares of the company's stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00. Following the transaction, the insider now directly owns 105,472,666 shares of the company's stock, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. Insiders have sold a total of 1,115,291 shares of company stock worth $355,901,728 in the last ninety days. Corporate insiders own 0.12% of the company's stock.

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Are Medtronic And Intuitive Surgical Poised For Big Growth? (LLY)
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Biden team, Eli Lilly condemn new Indiana abortion ban
Eli Lilly and Co. and the administration of President Joe Biden have condemned Indiana’s new ban on abortions
Eli Lilly's (LLY) Potential New Products Key to Growth
Eli Lilly and Company (NYSE:LLY) SVP Sells $199,752.00 in Stock
2 Dividend Stocks That Are Defying the Bear Market
US Politicians are Selling These 10 Stocks
Eli Lilly and (NYSE:LLY) Stock Rating Lowered by StockNews.com
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Ex-Dividend for 6/10 Dividend
5/13/2022
Dividend Payable
6/10/2022
Last Earnings
8/04/2022
Ex-Dividend for 9/9 Dividend
8/12/2022
Today
8/16/2022
Dividend Payable
9/09/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
53245710
Employees
35,000
Year Founded
1876

Price Target and Rating

Average Stock Price Forecast
$317.00
High Stock Price Forecast
$395.00
Low Stock Price Forecast
$264.00
Forecasted Upside/Downside
+2.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

Net Income
$5.58 billion
Pretax Margin
21.43%

Debt

Sales & Book Value

Annual Sales
$28.32 billion
Cash Flow
$9.46 per share
Book Value
$9.57 per share

Miscellaneous

Free Float
949,035,000
Market Cap
$294.85 billion
Optionable
Optionable
Beta
0.35

Social Links















LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and's stock price forecast for 2022?

17 Wall Street research analysts have issued 1 year target prices for Eli Lilly and's stock. Their LLY share price forecasts range from $264.00 to $395.00. On average, they predict the company's stock price to reach $317.00 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2022?

Eli Lilly and's stock was trading at $276.22 at the beginning of the year. Since then, LLY shares have increased by 13.7% and is now trading at $313.94.
View the best growth stocks for 2022 here
.

When is Eli Lilly and's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our LLY earnings forecast
.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Thursday, August, 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by $0.61. The company earned $6.49 billion during the quarter, compared to analysts' expectations of $6.85 billion. Eli Lilly and had a trailing twelve-month return on equity of 85.58% and a net margin of 19.58%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.87 earnings per share.
Read the conference call transcript
.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, June 27th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.98 per share on Friday, September 9th. This represents a $3.92 annualized dividend and a dividend yield of 1.25%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for LLY
.

Is Eli Lilly and a good dividend stock?

Eli Lilly and (NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.27%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 62.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 42.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and declared that its board has initiated a share repurchase program on Monday, May 3rd 2021, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of $7.90-$8.05 for the period, compared to the consensus EPS estimate of $8.08. The company issued revenue guidance of $28.80 billion-$29.30 billion, compared to the consensus revenue estimate of $28.27 billion.

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (10.96%), State Street Corp (3.52%), FMR LLC (3.41%), Primecap Management Co. CA (2.99%), Northern Trust Corp (1.15%) and Jennison Associates LLC (1.09%). Insiders that own company stock include Aarti S Shah, Alfonso G Zulueta, Alonzo Weems, Anne E White, David A Ricks, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $313.94.

How much money does Eli Lilly and make?

Eli Lilly and (NYSE:LLY) has a market capitalization of $298.30 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.27 on an earnings per share basis.

How many employees does Eli Lilly and have?

The company employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?
The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.